Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy / Bruera, G.; Pepe, F.; Malapelle, U.; Pisapia, P.; Dal Mas, A.; Di Giacomo, D.; Calvisi, G.; Troncone, G.; Ricevuto, E.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 28:(2017), p. vi14. [10.1093/annonc/mdx422.039]
Prevalence of KRAS, NRAS and BRAF mutations detected by massive parallel sequencing and differential clinical outcome in metastatic colorectal cancer (MCRC) patients (pts) treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy
Pepe, F.;Malapelle, U.;Pisapia, P.;Troncone, G.;
2017
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
